Last reviewed · How we verify
NT219 and ERBITUX® - Dose Escalation
At a glance
| Generic name | NT219 and ERBITUX® - Dose Escalation |
|---|---|
| Sponsor | TyrNovo Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NT219 and ERBITUX® - Dose Escalation CI brief — competitive landscape report
- NT219 and ERBITUX® - Dose Escalation updates RSS · CI watch RSS
- TyrNovo Ltd. portfolio CI